Study control, violators, inclusion criteria and defining explanatory and pragmatic trials

被引:55
|
作者
McMahon, AD [1 ]
机构
[1] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland
关键词
randomized controlled trial; pragmatic trial; explanatory trial; inclusion criteria; representativeness; intention to treat;
D O I
10.1002/sim.1120
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Important differences between explanatory and pragmatic studies were originally argued by Schwartz and Lellouch. Three important differences between the two types of study involve study control, study violators and inclusion criteria. It was originally argued that explanatory studies are highly controlled, and pragmatic studies may be looser and more like 'real life'. It was argued that an explanatory study should only analyse those receiving treatment, and a pragmatic study would analyse all randomized patients. Explanatory trials are said to use homogeneous groups, and pragmatic studies have less selection (better generalizability). Some suggestions are put forward to update the original distinctions between these two attitudes for future study design. Poor study control is undesirable (but might be necessary) and should not be welcomed as pragmatic. The intention-to-treat strategy is now considered as standard for nearly all trials. Homogeneity is a red herring for studies in humans. Inclusion criteria should be minimized and they should not be used to justify claims of representativeness. Routine criticism of randomized controlled trials for being unrepresentative is unwarranted. We should accept that most trials in humans are 'explanatory'. The division line should be moved, so that pragmatic studies are in the domain of non-therapeutics and complex treatments. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:1365 / 1376
页数:12
相关论文
共 50 条
  • [41] THE CASE FOR LOOSE INCLUSION CRITERIA IN CLINICAL-TRIALS
    BUYSE, ME
    ACTA CHIRURGICA BELGICA, 1990, (03) : 129 - 131
  • [42] Should criteria for inclusion in cancer clinical trials be expanded?
    Gerber, David E.
    Pruitt, Sandi L.
    Halm, Ethan A.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (04) : 289 - 291
  • [43] Conceptualizing E-Inclusion in Europe: An Explanatory Study
    Weerakkody, Vishanth
    Dwivedi, Yogesh K.
    El-Haddadeh, Ramzi
    Almuwil, Ahlam
    Ghoneim, Ahmad
    INFORMATION SYSTEMS MANAGEMENT, 2012, 29 (04) : 305 - 320
  • [44] PRAGMATIC AND EXPLANATORY TRIALS IN THE EVALUATION OF THE EXPERIMENTAL NATIONAL-HEALTH-SERVICE NURSING-HOMES
    BOND, J
    ATKINSON, A
    GREGSON, BA
    NEWELL, DJ
    AGE AND AGEING, 1989, 18 (02) : 89 - 95
  • [45] Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
    Bossie, Cynthia A.
    Alphs, Larry D.
    Correll, Christoph U.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (05) : 272 - 281
  • [46] The current dilemma with spirometric inclusion criteria for asthma drug trials
    Cockcroft, DW
    Jokic, R
    Marciniuk, DD
    Fitzpatrick, MF
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1997, 79 (03) : 226 - 228
  • [47] Spirometric inclusion criteria of COPD patients in randomized clinical trials
    Fabbri, Leonardo M.
    RESPIRATORY MEDICINE, 2012, 106 (06) : 912 - 913
  • [48] Inclusion and Exclusion Criteria in Randomized Controlled Trials of Psychotherapy for PTSD
    Ronconi, Julia M.
    Shiner, Brian
    Watts, Bradley V.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2014, 20 (01) : 25 - 37
  • [49] Inclusion criteria used in trials of people with progressive multiple sclerosis
    Dubuisson, Nicolas
    Marta, Monica
    Gnanapavan, Sharmilee
    Turner, Benjamin
    Baker, David
    Thomson, Alison
    Schmierer, Klaus
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (03) : 279 - 283
  • [50] A systematic review of inclusion criteria for clinical trials of atopic dermatitis
    Chopra, R.
    Vakharia, P.
    Silverberg, J. I.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S66 - S66